posted on 2021-02-01, 16:21authored byAda AdminAda Admin, Rajakrishnan Veluthakal, Eunjin Oh, Miwon Ahn, Diti Chatterjee-Bhowmick, Debbie C. Thurmond
Enrichment
of human islets with Syntaxin 4 (STX4) improves functional β-cell mass through
a nuclear factor- kB (NF-kB)-dependent
mechanism. However, the detailed mechanisms underlying the protective effect of
STX4 are unknown. To determine the signaling events linking STX4 enrichment and
downregulation of NF-kB activity, STX4 was overexpressed
in human islets, EndoC-βH1 and INS-1 832/13 cells in culture, and the cells
were challenged with the proinflammatory cytokines interleukin-1β, tumor
necrosis factor-a and interferon-g,
individually and in combination. STX4 expression suppressed cytokine-induced
proteasomal degradation of IkBβ but not IkBa.
Inhibition of IKKβ prevented IkBβ degradation, suggesting that
IKKβ phosphorylates IkBβ. Moreover, the IKKβ inhibitor,
as well as a proteosomal degradation inhibitor, prevented the loss of STX4
caused by cytokines. This suggests that STX4 may be phosphorylated by IKKβ in
response to cytokines, targeting STX4 for proteosomal degradation. Expression
of a stabilized form of STX4 further protected IkBβ from proteasomal degradation,
and like wildtype STX4, stabilized STX4 coimmunoprecipitated with IkBβ and
the NF-kB p50 subunit. This work proposes a novel pathway
wherein STX4 regulates cytokine-induced NF-kB signaling in β-cells via
associating with and preventing IkBβ degradation, suppressing
chemokine expression, and protecting islet β-cells from cytokine-mediated
dysfunction and demise.
Funding
This study was supported by grants from the National Institutes of Health (DK067912, DK112917 and DK102233 to D.C.T.), the Juvenile Diabetes Research Foundation (17-2013-454 to D.C.T.), and the Wanek Project to Cure Type 1 Diabetes at the City of Hope.